

Modelling long-term COVID-19 hospital admission dynamics using immune protection waning data

 Bastien Reyné^{1*},  Mircea T. Sofonea¹⁼,  Samuel Alizon^{1,2=}

1 MIVEGEC, Univ. Montpellier, CNRS, IRD — Montpellier, France

2 CIRB, College de France, CNRS, INSERM, Université PSL — Paris, France

* corresponding author : bastien.reyne@ird.fr

= equal contribution

Abstract

Immune waning is key to the timely anticipation of COVID-19 long-term dynamics. We assess the impact of periodic vaccination campaigns using a compartmental epidemiological model with multiple age structures and parameterised using empiric time-dependent vaccine protection data. Despite the inherent uncertainty, we show that vaccination on its own, especially if restricted to individuals over 60 years old, seems insufficient to prevent a large number of hospital admissions.

Introduction

From the beginning, Covid-19 pandemic management had to deal with numerous unknowns and strongly relied on mathematical modelling to guide the implementation of non-pharmaceutical interventions (NPIs). The rapid discovery and implementation of efficient vaccines led to the hope that public health policy planning could soon return to normal. However, long-term forecasts are difficult because vaccine protection has been reported to decrease with time [UKHSA, 2022]. Furthermore, the emergence of variants of concerns (VOC) raises major concerns regarding epidemic management. This is particularly true for lineages from the Omicron variant that exhibit strong immune escape properties.

The waning of immune protection is challenging to capture with classical compartmental models because it implies an exponential increase in the number of model compartments, which makes parameterization arbitrary. We extend a non-Markovian approach [Reyné et alii, 2022], that readily accounts for the time spent in each compartment. By using published data, we explore long-term epidemic dynamics in a qualitative way. In our scenarios, we account for immunity waning as well as Omicron-specific phenotypic traits and compare four vaccination campaign strategies.

An epidemiological model with time structures

We analyse an epidemiological compartmental model (Figure 1A) in which susceptible individuals of age a (the density of which is denoted S_a) can either become fully vaccinated (V_a), or contract a mild (I_a^m) or severe infection (I_a^s). Mildly-infected individuals always recover and move to the compartment R_a . Both recovered and vaccinated individuals can be (re)infected, but at a reduced rate compared to susceptible individuals. If this (re)infection is mild, individuals move to a separate compartment (I_a^{mv}) to account for a potential immunity-induced reduction in infectiousness. Vaccinated and recovered individuals may be (re)vaccinated and move to the booster compartment (B_a), where their protection increases. Finally, severely infected (I_a^s) and previously immunised mildly infected individuals (I_a^{mv}) also end up in the booster compartment upon recovery. Overall, the boosted compartment consists of individuals with booster vaccination dose(s), two

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.




Figure 1: **A. Flowchart of the memory-based model with immune waning.** Arrows show transitions between compartments. S_a stands for Susceptible individuals of age a , I_{ai}^m , I_{ai}^s , I_{ai}^d and I_{ai}^{mv} stand respectively for mildly/severely/severely-that-will-die/mildly-partly-immune infected individuals of age a infected since i days, V_{ak} stands for Vaccinated individuals of age a vaccinated k days ago, R_{aj} stands for Recovered individuals of age a that cleared the disease j days ago and finally B_{al} stands for individuals of age a that received a booster vaccine dose ℓ days ago. Orange arrows show some of the transitions that depend on the time spent in the compartment (here ℓ days) that are parametrized through real immune waning data shown on panel B. **B. Immunity waning implementation.** Dots corresponds to real data from UKHSA [2022] for the Pfizer/BioNTech vaccine (BNT162b2) after a booster dose. The lines correspond to the baseline of the immunity decrease model implementation and the shaded areas to the uncertainty used within the sensitivity analysis. Here, we show the protection against an Omicron VOC infection for individuals that received a booster dose.

The model records the time spent by the individuals in each compartment. Knowing the time since vaccination (k) for vaccinated individuals, the time since clearance (j) for recovered individuals, and the time since the entry into the booster compartment (l), allows us to readily account for the waning in immune protection.

This model is based on a system of partial differential equations (Appendix S3). Its parameterization reflects the French epidemic and the Omicron VOC (Table S1) [Sofonea et alii, 2022].

Contact rates were allowed to vary with time and were fitted using the hospital admissions time series up to May, 6th 2022. Following a parsimony principle, we used the last fitted value as the baseline until the rest of the simulations, since spontaneous or policy-induced behavioural changes are unpredictable.

External factors, such as the weather, are known to impact transmission dynamics [Ma et alii, 2021]. We include this seasonality by assuming sinusoidal variations such that in summer the contact rate is decreased to -10% and increased by $+10\%$ in the winter.

Table 1: **Description of the model parameters and their default value.** For each parameter, we indicate the default value used, the range in the sensitivity analyses, and the references.

Parameter	Value retained	Range for SA	Reference
Generation time	Weibull(2.83, 5.67)	Not included	Ferretti et alii [2020]
Omicron GT	Gamma(1.84, 0.53)	See Appendix S4	UKSHA [2022]
Proportion of severe cases (p_a), IFR (ifr_a)	0.0113 (mean), 0.0022 (mean)	Not included	Verity et alii [2020]
α VOC increase in virulence	1.65	Not included	Challen et alii [2021] ; Davies et alii [2021]
δ VOC increase in virulence	2.08	Not included	Fisman and Tuite [2021]
Omicron VOC decrease in virulence	0.33	Not included	Nyberg et alii [2022]
Seasonality	0.1	[0 – 0.2]	Ma et alii [2021]
Total number of vaccinated (initial two doses)	$5.21 \cdot 10^7$	$[5 \cdot 10^7 - 5.42 \cdot 10^7]$	French Minister of Health website (visited on 2021-10-28)
Vaccine efficacy	See Appendix S4	+ / - 5%	UKHSA [2022]
Transmission reduction	0.5	[0.45 – 0.55]	Bosetti et alii [2022]
Initial proportion of recovered	0.149	Not included	Hozé et alii [2021]
Contact matrix	See Reyné et alii [2022]		Béraud et alii [2015] ; Reyné et alii [2022]

Immune waning

In contrast to earlier models, we could calibrate immunity waning using epidemiological data [UKHSA \[2022\]](#). More precisely, we used time series of vaccine protection (whether initial doses or boosters) against both symptomatic disease and hospitalisation, for both Delta and Omicron VOC. We fitted linear models on the different time series (Figure 1B).

Vaccination campaign scenarios

All vaccinated individuals are assumed to receive a booster dose 6 months after entering the vaccinated (V_a) compartment. Then, we investigate four different scenarios.

In Scenario A, boosted individuals are not vaccinated again. This leads to a high level of daily hospital admissions (Figure 2A) with yearly oscillations attributable to seasonality.

Scenario B consists in implementing annual vaccination campaigns before winter (in September and October) but only for individuals above 60 years old. This improves the overall situation compared to not vaccinating but the median number of hospital admissions always remains above 500 per day (Figure 2B).

Third, we extend the yearly vaccination campaign to all the population (Figure 2C). This further lowers the number of daily hospital admissions and it also yields an epidemic wave in the early spring.

Finally, the fourth scenario assumes two national vaccine campaigns per year (in September – October and in March – April) for all the population (Figure 2D). This lowers the number of daily hospital admissions even further but it does not prevent two marked epidemic waves per year.

Figure 3 shows the annual total number of hospital admissions for each scenario. As expected, the more the people are vaccinated, the more the daily hospital admissions lower.




Figure 2: Median number of COVID-19 hospital admissions in four vaccination campaign scenarios. Blue dots corresponds to real data and green shaded areas to vaccination campaigns periods. The four panels correspond to scenarios without additional booster (A), with an annual vaccination campaign in September-October for every individuals above 60 y.o. (B), an annual vaccination campaign in September-October for the whole population (C), and bi-annual vaccination campaign for the whole population (in September-October and in March-April).




Figure 3: Total number of hospital admissions per year for four vaccination scenarios. Blue line corresponds to real data for 2021. The four type of boxplots correspond to scenarios without additional booster (A), with an annual vaccination campaign in September-October for every individuals above 60 y.o. (B), an annual vaccination campaign in September-October for the whole population (C), and bi-annual vaccination campaign for the whole population (in September-October and in March-April).

Discussion

COVID-19 management will now face the challenge of post-infection and post-vaccination immune waning combined with the emergence risk of new VOCs. We investigated the behaviour of long-term epidemiological dynamics, assuming periodic vaccination campaigns over the next three years.

Long term scenarios are obviously extremely uncertain but they can provide valuable insights. Also in the French context, [Bosetti et alii \[2022\]](#), tried to determine under what booster administration and NPIs implementation a new epidemic could be contained. However, their work was done before the Omicron phenotypical traits were known, and only on a six-month horizon. Regarding long-term dynamics, [Kissler et alii \[2020\]](#) investigated the potential effects of the seasonality observed in other epidemics than that of SARS-CoV-2. They highlighted the need for NPIs, but their results were obtained before vaccine implementation and the emergence of the different VOCs. Finally, [Saad-Roy et alii \[2021\]](#) studied different vaccine administration patterns for several scenarios of immunity duration, but it was done at the time there was no data on immune protection waning.

Leaning on immune protection data, we show that immune waning may cause yearly epidemic hospitalization peaks comparable to the largest one seen in 2021. Vaccination appears to mitigate this impact. However, vaccination itself seems insufficient to suppress the epidemic.

These results should be taken with caution due to the numerous sources of uncertainty (Appendix S1). In particular, comparisons should be restricted to our four scenarios that share the same core assumptions.

The sensitivity analyses (Appendix S2) highlight the main sources of uncertainty. As discussed by [Reyné et alii \[2022\]](#), the uncertainty mostly originates from factors that are difficult to predict such as the time-varying contact matrix or the potential seasonality. Regarding virus-related model parameters, the reduction in contagiousness due to immunity, which is difficult to estimate [[Bosetti et alii, 2022](#); [Prunas et alii, 2022](#)], contributes to most of the variance in the model output.

Finally, we assumed that the intensity of non-pharmaceutical interventions will remain identical to that enforced in early spring 2022. This discards any changes in government policies that would probably be required since vaccination on its own is unlikely to be sufficient to avoid a strong burden for hospitals in terms of COVID-19 admissions. Future work is required to identify the optimal balance between vaccination campaigns and other types of NPIs such as improving indoor air quality or mask-wearing.

Acknowledgements

The authors acknowledge the ISO 9001 certified IRD i-Trop HPC (South Green Platform) at IRD Montpellier for providing HPC resources that have contributed to the research results reported within this paper. We thank all the ETE modelling team for discussions and apologize to Baptiste Elie for that reckless `rm -r *`. BR is funded by the Ministère de l'Enseignement Supérieur et de la Recherche.

References

- Béraud, Guillaume et alii (July 2015). “The French Connection: The First Large Population-Based Contact Survey in France Relevant for the Spread of Infectious Diseases”. en. In: *PLOS ONE* 10.7. Publisher: Public Library of Science, e0133203. ISSN: 1932-6203. DOI: [10.1371/journal.pone.0133203](https://doi.org/10.1371/journal.pone.0133203). URL: <https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0133203> (visited on 06/03/2021).
- Bosetti, Paolo et alii (Jan. 2022). “Impact of booster vaccination on the control of COVID-19 Delta wave in the context of waning immunity: application to France in the winter 2021/22”. en. In: *Eurosurveillance* 27.1. Publisher: European Centre for Disease Prevention and Control, page 2101125. ISSN: 1560-7917. DOI: [10.2807/1560-7917.ES.2022.27.1.2101125](https://doi.org/10.2807/1560-7917.ES.2022.27.1.2101125). URL: <https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2022.27.1.2101125> (visited on 03/17/2022).

- Challen, Robert et alii (Mar. 2021). “Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study”. en. In: *BMJ* 372. Publisher: British Medical Journal Publishing Group Section: Research, n579. ISSN: 1756-1833. DOI: [10.1136/bmj.n579](https://doi.org/10.1136/bmj.n579). URL: <https://www.bmj.com/content/372/bmj.n579> (visited on 06/02/2021).
- Davies, Nicholas G. et alii (May 2021). “Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7”. en. In: *Nature* 593.7858. Number: 7858 Publisher: Nature Publishing Group, pages 270–274. ISSN: 1476-4687. DOI: [10.1038/s41586-021-03426-1](https://doi.org/10.1038/s41586-021-03426-1). URL: <https://www.nature.com/articles/s41586-021-03426-1> (visited on 06/02/2021).
- Ferretti, Luca et alii (May 2020). “Quantifying SARS-CoV-2 transmission suggests epidemic control with digital contact tracing”. en. In: *Science* 368.6491. Publisher: American Association for the Advancement of Science Section: Research Article. ISSN: 0036-8075, 1095-9203. DOI: [10.1126/science.abb6936](https://doi.org/10.1126/science.abb6936). URL: <https://science.sciencemag.org/content/368/6491/eabb6936> (visited on 06/01/2021).
- Fisman, David N. and Ashleigh R. Tuite (Oct. 2021). “Evaluation of the relative virulence of novel SARS-CoV-2 variants: a retrospective cohort study in Ontario, Canada”. en. In: *CMAJ* 193.42. Publisher: CMAJ Section: Research, E1619–E1625. ISSN: 0820-3946, 1488-2329. DOI: [10.1503/cmaj.211248](https://doi.org/10.1503/cmaj.211248). URL: <https://www.cmaj.ca/content/193/42/E1619> (visited on 11/03/2021).
- Hozé, Nathanaël et alii (June 2021). “Monitoring the proportion of the population infected by SARS-CoV-2 using age-stratified hospitalisation and serological data: a modelling study”. en. In: *The Lancet Public Health* 6.6, e408–e415. ISSN: 2468-2667. DOI: [10.1016/S2468-2667\(21\)00064-5](https://doi.org/10.1016/S2468-2667(21)00064-5). URL: <https://www.sciencedirect.com/science/article/pii/S2468266721000645> (visited on 06/07/2021).
- Kissler, Stephen M. et alii (May 2020). “Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period”. In: *Science* 368.6493. Publisher: American Association for the Advancement of Science, pages 860–868. DOI: [10.1126/science.abb5793](https://doi.org/10.1126/science.abb5793). URL: <https://www.science.org/doi/10.1126/science.abb5793> (visited on 03/21/2022).
- Ma, Yiqun et alii (June 2021). “Role of meteorological factors in the transmission of SARS-CoV-2 in the United States”. en. In: *Nature Communications* 12.1, page 3602. ISSN: 2041-1723. DOI: [10.1038/s41467-021-23866-7](https://doi.org/10.1038/s41467-021-23866-7). URL: <https://www.nature.com/articles/s41467-021-23866-7> (visited on 09/25/2021).
- Nyberg, Tommy et alii (2022). “Comparative Analysis of the Risks of Hospitalisation and Death Associated with SARS-CoV-2 Omicron (B.1.1.529) and Delta (B.1.617.2) Variants in England”. en. In: *SSRN Electronic Journal*. ISSN: 1556-5068. DOI: [10.2139/ssrn.4025932](https://doi.org/10.2139/ssrn.4025932). URL: <https://www.ssrn.com/abstract=4025932> (visited on 03/15/2022).
- Prunas, Ottavia et alii (Mar. 2022). “Vaccination with BNT162b2 reduces transmission of SARS-CoV-2 to household contacts in Israel”. In: *Science* 375.6585. Publisher: American Association for the Advancement of Science, pages 1151–1154. DOI: [10.1126/science.abl4292](https://doi.org/10.1126/science.abl4292). URL: <https://www.science.org/doi/10.1126/science.abl4292> (visited on 03/24/2022).
- Reyné, Bastien et alii (Mar. 2022). “Non-Markovian modelling highlights the importance of age structure on Covid-19 epidemiological dynamics”. en. In: *Mathematical Modelling of Natural Phenomena*. Publisher: EDP Sciences. ISSN: 0973-5348, 1760-6101. DOI: [10.1051/mmnp/2022008](https://doi.org/10.1051/mmnp/2022008). URL: <https://www.mmnp-journal.org/articles/mmnp/abs/forth/mmnp220048/mmnp220048.html> (visited on 03/15/2022).
- Saad-Roy, Chadi M. et alii (Mar. 2021). “Epidemiological and evolutionary considerations of SARS-CoV-2 vaccine dosing regimes”. en. In: *Science*, eabg8663. ISSN: 0036-8075, 1095-9203. DOI: [10.1126/science.abg8663](https://doi.org/10.1126/science.abg8663). URL: <https://www.sciencemag.org/lookup/doi/10.1126/science.abg8663> (visited on 03/23/2021).
- Sofonea, Mircea T et alii (2022). “Analyzing and modeling the spread of SARS-CoV-2 Omicron lineages BA.1 and BA.2 in France (September 1, 2021, to February 28, 2022)”. In: *Emerg Infect Dis* 28.7. DOI: [10.3201/eid2807.220033](https://doi.org/10.3201/eid2807.220033).

- UKHSA (2022). “COVID-19 vaccine surveillance report - week 16”. en. In: *Report*, page 22. URL: <https://www.gov.uk/government/publications/covid-19-vaccine-weekly-surveillance-reports>.
- UKSHA (2022). “SARS-CoV-2 variants of concern and variants under investigation”. en. In: page 33. URL: <https://www.gov.uk/government/publications/investigation-of-sars-cov-2-variants-technical-briefings>.
- Verity, Robert et alii (June 2020). “Estimates of the severity of coronavirus disease 2019: a model-based analysis”. English. In: *The Lancet Infectious Diseases* 20.6. Publisher: Elsevier, pages 669–677. ISSN: 1473-3099, 1474-4457. DOI: [10.1016/S1473-3099\(20\)30243-7](https://doi.org/10.1016/S1473-3099(20)30243-7). URL: [https://www.thelancet.com/journals/laninf/article/PIIS1473-3099\(20\)30243-7/abstract](https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30243-7/abstract) (visited on 06/02/2021).

S1 Supplementary results




Figure S1: **Detailed output of Scenario A (no additional vaccination).** Blue dots corresponds to real data. The black line correspond to the median trajectory. Lighter shaded area correspond to the 95% confidence interval while the darker area correspond to the interquartile range. The horizontal blue line indicates the highest national incidence in hospital admissions reached during the first COVID-19 wave in France.




Figure S2: **Detailed output of Scenario B (yearly vaccination of individuals of more than 60 years old).** Green shaded areas correspond to vaccination campaigns periods for individuals above 60 y.o. See Figure S1 for additional details.




Figure S3: **Detailed output of Scenario C (yearly vaccination of all the population).** See Figure S2 for additional details.




Figure S4: **Detailed output of Scenario D (vaccination of all the population twice a year).** See Figure S2 for additional details.

S2 Sensitivity analysis




Figure S5: **Global sensitivity analysis for Scenario A.** The graphs shows the origin of the variance captured by each model parameter using Sobol indices (see [Reyné et alii, 2022](#) for methodological details). A large part of the variations originates from the unknowns in the contact matrix between ages, as in [Reyné et alii, 2022](#). The magnitude of seasonality also matters for the long-term trends, as well as the transmission rate (i.e. the intensity of the NPIs).




Figure S6: **Global sensitivity analysis for Scenario B.** See for details.




Figure S7: Global sensitivity analysis for Scenario C. See for details.




Figure S8: Global sensitivity analysis for Scenario D. See for details.

S3 Model equations

The model partial differential equations system is given by:

$$\frac{\partial S(t, a)}{\partial t} = -\lambda(t, a)S(t, a) - \rho(t, a)S(t, a) \quad (\text{S1})$$

$$\left(\frac{\partial I^m(t, a, i)}{\partial t} + \frac{\partial I^m(t, a, i)}{\partial i} \right) = -\gamma^m(a, i)I^m(t, a, i), \quad (\text{S2})$$

$$\left(\frac{\partial I^s(t, a, i)}{\partial t} + \frac{\partial I^s(t, a, i)}{\partial i} \right) = -\gamma^s(a, i)I^s(t, a, i), \quad (\text{S3})$$

$$\left(\frac{\partial I^d(t, a, i)}{\partial t} + \frac{\partial I^d(t, a, i)}{\partial i} \right) = -\mu(a, i)I^d(t, a, i), \quad (\text{S4})$$

$$\left(\frac{\partial R(t, a, j)}{\partial t} + \frac{\partial R(t, a, j)}{\partial j} \right) = -\rho(t, a)R(t, a, j) - (1 - \varepsilon^R(a, j))\lambda(t, a)R(t, a, j) \quad (\text{S5})$$

$$\left(\frac{\partial V(t, a, k)}{\partial t} + \frac{\partial V(t, a, k)}{\partial k} \right) = -(1 - \varepsilon^V(a, k))\lambda(t, a)V(t, a, k) \quad (\text{S6})$$

$$\left(\frac{\partial I^{mv}(t, a, i)}{\partial t} + \frac{\partial I^{mv}(t, a, i)}{\partial i} \right) = -\gamma^{mv}(a, i)I^{mv}(t, a, i), \quad (\text{S7})$$

$$\left(\frac{\partial B(t, a, \ell)}{\partial t} + \frac{\partial B(t, a, \ell)}{\partial \ell} \right) = -(1 - \varepsilon^B(a, \ell))\lambda(t, a)B(t, a, \ell) \quad (\text{S8})$$

with

$$\lambda(t, a) = \int_0^{a_{\max}} (1 - c)^2 K(a, a') \int_0^{i_{\max}} \left[\beta^m(a', i)I^m(t, a', i) + \beta^s(a', i)I^s(t, a', i) + \beta^d(a', i)I^d(t, a', i) + \beta^{mv}(a', i)(1 - \xi(a'))I^{mv}(t, a', i) \right] di da', \quad (\text{S9})$$

for any $(t, a, i, j, k) \in \mathbb{R}^+ \times [0, a_{\max}] \times [0, i_{\max}] \times [0, j_{\max}] \times [0, k_{\max}]$.

The parameter notations are the following:

- ρ is the vaccination rate,
- $\gamma^{m,s}$ the recovery rates for respectively mildly and severely infected individuals,
- μ is the death rate,
- $\varepsilon^{R,V,B}$ the immunity-induced reduction of risk of infection for individuals respectively in the R , V and B compartments,
- c the intensity of NPI policy,
- $K(a, a')$ the contact matrix coefficient between age groups a and a' ,
- $\beta^{m,s,d,mv}$ the generation time distributions, and
- ξ the immunity-induced reduction in transmission (for 'breakthrough' infections).

The previous system is coupled with the following boundary conditions:

$$R(t, a, 0) = \int_0^{i_{\max}} \gamma^m(a, i) I^m(t, a, i) di, \quad (\text{S10})$$

$$V(t, a, 0) = \rho(t, a) S(t, a), \quad (\text{S11})$$

$$B(t, a, 0) = \rho(t, a) \int_0^{j_{\max}} R(t, a, j) dj + \int_0^{i_{\max}} [\gamma^{mv}(a, i) I^m v(t, a, i) + \gamma^m(a, i) I^m(t, a, i)] di, \quad (\text{S12})$$

$$I^m(t, a, 0) = (1 - p_a) \lambda(t, a) S(t, a), \quad (\text{S13})$$

$$I^s(t, a, 0) = p_a \left(1 - \frac{\text{ifr}_a}{p_a}\right) \lambda(t, a) \left[S(t, a) + \int_0^{k_{\max}} (1 - \varepsilon^V(a, k))(1 - \nu^V(a, k)) V(t, a, k) dk + \int_0^{j_{\max}} (1 - \varepsilon^R(a, j))(1 - \nu^R(a, j)) R(t, a, j) dj + \int_0^{\ell_{\max}} (1 - \varepsilon^B(a, \ell))(1 - \nu^B(a, \ell)) B(t, a, \ell) d\ell \right], \quad (\text{S14})$$

$$I^d(t, a, 0) = \text{ifr}_a \lambda(t, a) \left[S(t, a) + \int_0^{k_{\max}} (1 - \varepsilon^V(a, k))(1 - \nu^V(a, k)) V(t, a, k) dk + \int_0^{j_{\max}} (1 - \varepsilon^R(a, j))(1 - \nu^R(a, j)) R(t, a, j) dj + \int_0^{\ell_{\max}} (1 - \varepsilon^B(a, \ell))(1 - \nu^B(a, \ell)) B(t, a, \ell) d\ell \right], \quad (\text{S15})$$

$$I^{mv}(t, a, 0) = \lambda(t, a) \left[\int_0^{k_{\max}} (1 - \varepsilon^V(a, k))(1 - \nu^V(a, k)) V(t, a, k) dk + \int_0^{j_{\max}} (1 - \varepsilon^R(a, j))(1 - \nu^R(a, j)) R(t, a, j) dj + \int_0^{\ell_{\max}} (1 - \varepsilon^B(a, \ell))(1 - \nu^B(a, \ell)) B(t, a, \ell) d\ell \right], \quad (\text{S16})$$

where

- p_a is the probability of developing a severe form,
- ifr_a is the infection fatality rate, and
- $\nu^{V,R,B}$ is the immunity-induced reduction of virulence for individuals respectively in the R , V , and B compartments.

S4 Omicron related parameters and vaccine efficacy

Regarding the omicron generation interval, we used the data provided by [UKSHA \[2022\]](#). In particular, we fitted different Gamma distributions on the non-parametric data available. We tested different parameters combinations for the Gamma distribution to explore a range of generation time distributions that reflect the epidemiology of both BA.1 and BA.2 variants. In Figure S9, we show a subset of these Gamma distributions explored within the sensitivity analysis.

Regarding the parameterisation of vaccine effectiveness, we used data provided by the [UKHSA \[2022\]](#) report (https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1070356/Vaccine-surveillance-report-week-16.pdf). The raw data




Figure S9: **Omicron generation time.** Shaded areas data originate from the [UKSHA \[2022\]](#) report. The lines correspond to a subset of the Gamma distributions used in the sensitivity analysis. The thicker line corresponds to the baseline Gamma distribution.

was not available so we used the online tool WebPlot Digitalizer (<https://apps.automeris.io/wpd/>) to retrieve the values. For simplicity, we assumed that individuals received the Pfizer/BioNTech (BNT162b2) vaccine, which was the most widespread in France. We fitted linear models on vaccine effectiveness against symptomatic disease and hospital admissions for the Delta and Omicron VOC. Note that the intrinsic virulence of Omicron is assumed to be divided by 3 (parameter p_a in the model) compared to Delta following UK data [Nyberg et alii, 2022](#).

In the sensitivity analysis, we included variations in vaccine protection against symptomatic disease and against hospitalization risk. We used the linear model best fit as our baseline and generated variation by applying a coefficient to the intercept spanning from -0.05 to 0.05 (Figure 1B).

The reduction of transmission (in so-called ‘breakthrough’ infections) was assumed to be of 50% for vaccinated individuals, as in others modelling works [Bosetti et alii, 2022](#). This reduction in transmission was also applied to recovered people that got reinfected.

S5 Model parameters with sensitivity analyses ranges

We show in Table S1 the baseline for the different parameters and the range used for parameters included in the sensitivity analysis. Several parameters were not included in the sensitivity analysis, as they already were included in that in [Reyné et alii \[2022\]](#). We expect these earlier results to hold and these parameters have limited relevance in the contact of the Omicron epidemic.

Table S1: **Model parameters.** For each parameter, we indicate the default value used and the references used.

Parameter	Value retained	Range for SA	Reference
Generation time	Weibull(2.83, 5.67)	Not included	Ferretti et alii [2020]
Omicron GT	Gamma(1.84, 0.53)	See Appendix S4	UKSHA [2022]
Proportion of severe cases (p_a), IFR (ifr_a)	0.0113 (mean), 0.0022 (mean)	Not included	Verity et alii [2020]
α VOC increase in virulence	1.65	Not included	Challen et alii [2021] ; Davies et alii [2021]
δ VOC increase in virulence	2.08	Not included	Fisman and Tuite [2021]
Seasonality	0.05	[0 – 0.1]	
Mild recovery rate	Adapted	Not included	Salje et alii [2020]
Severe recovery rate	Adapted	Not included	Salje et alii [2020] ; Lefrancq et alii [2021]
Vaccination rate	Fitted	—	https://data.gouv.fr
Total number of vaccinated (initial two doses)	$5.21 \cdot 10^7$	$[5 \cdot 10^7 - 5.42 \cdot 10^7]$	French Minister of Health website (visited on 2021-10-28)
Total severity reduction	See Appendix S4		UKHSA [2022]
Infection immunity	See Appendix S4	+/- 5%	UKHSA [2022]
Transmission reduction	0.5	[0.45 – 0.55]	[Bosetti et alii, 2022]
Initial proportion of recovered	0.149	Not included	Hozé et alii [2021]
Age structure	Real data	—	https://www.insee.fr/fr/statistiques/2381474
Contact matrix	—	See Reyné et alii [2022]	Béraud et alii [2015] ; Reyné et alii [2022]

References

- Béraud, Guillaume et alii (July 2015). “The French Connection: The First Large Population-Based Contact Survey in France Relevant for the Spread of Infectious Diseases”. en. In: *PLOS ONE* 10.7. Publisher: Public Library of Science, e0133203. ISSN: 1932-6203. DOI: [10.1371/journal.pone.0133203](https://doi.org/10.1371/journal.pone.0133203). URL: <https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0133203> (visited on 06/03/2021).
- Bosetti, Paolo et alii (Jan. 2022). “Impact of booster vaccination on the control of COVID-19 Delta wave in the context of waning immunity: application to France in the winter 2021/22”. en. In: *Eurosurveillance* 27.1. Publisher: European Centre for Disease Prevention and Control, page 2101125. ISSN: 1560-7917. DOI: [10.2807/1560-7917.ES.2022.27.1.2101125](https://doi.org/10.2807/1560-7917.ES.2022.27.1.2101125). URL: <https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2022.27.1.2101125> (visited on 03/17/2022).
- Challen, Robert et alii (Mar. 2021). “Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study”. en. In: *BMJ* 372. Publisher: British Medical Journal Publishing Group Section: Research, n579. ISSN: 1756-1833. DOI: [10.1136/bmj.n579](https://doi.org/10.1136/bmj.n579). URL: <https://www.bmj.com/content/372/bmj.n579> (visited on 06/02/2021).
- Davies, Nicholas G. et alii (May 2021). “Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7”. en. In: *Nature* 593.7858. Number: 7858 Publisher: Nature Publishing Group, pages 270–

274. ISSN: 1476-4687. DOI: [10.1038/s41586-021-03426-1](https://doi.org/10.1038/s41586-021-03426-1). URL: <https://www.nature.com/articles/s41586-021-03426-1> (visited on 06/02/2021).
- Ferretti, Luca et alii (May 2020). “Quantifying SARS-CoV-2 transmission suggests epidemic control with digital contact tracing”. en. In: *Science* 368.6491. Publisher: American Association for the Advancement of Science Section: Research Article. ISSN: 0036-8075, 1095-9203. DOI: [10.1126/science.abb6936](https://doi.org/10.1126/science.abb6936). URL: <https://science.sciencemag.org/content/368/6491/eabb6936> (visited on 06/01/2021).
- Fisman, David N. and Ashleigh R. Tuite (Oct. 2021). “Evaluation of the relative virulence of novel SARS-CoV-2 variants: a retrospective cohort study in Ontario, Canada”. en. In: *CMAJ* 193.42. Publisher: CMAJ Section: Research, E1619–E1625. ISSN: 0820-3946, 1488-2329. DOI: [10.1503/cmaj.211248](https://doi.org/10.1503/cmaj.211248). URL: <https://www.cmaj.ca/content/193/42/E1619> (visited on 11/03/2021).
- Hozé, Nathanaël et alii (June 2021). “Monitoring the proportion of the population infected by SARS-CoV-2 using age-stratified hospitalisation and serological data: a modelling study”. en. In: *The Lancet Public Health* 6.6, e408–e415. ISSN: 2468-2667. DOI: [10.1016/S2468-2667\(21\)00064-5](https://doi.org/10.1016/S2468-2667(21)00064-5). URL: <https://www.sciencedirect.com/science/article/pii/S2468266721000645> (visited on 06/07/2021).
- Lefrancq, Noémie et alii (2021). “Evolution of outcomes for patients hospitalised during the first 9 months of the SARS-CoV-2 pandemic in France: A retrospective national surveillance data analysis”. en. In: *The Lancet Regional Health - Europe* 5, page 100087. ISSN: 26667762. DOI: [10.1016/j.lanepe.2021.100087](https://doi.org/10.1016/j.lanepe.2021.100087). URL: <https://linkinghub.elsevier.com/retrieve/pii/S2666776221000648> (visited on 04/30/2021).
- Nyberg, Tommy et alii (2022). “Comparative Analysis of the Risks of Hospitalisation and Death Associated with SARS-CoV-2 Omicron (B.1.1.529) and Delta (B.1.617.2) Variants in England”. en. In: *SSRN Electronic Journal*. ISSN: 1556-5068. DOI: [10.2139/ssrn.4025932](https://doi.org/10.2139/ssrn.4025932). URL: <https://www.ssrn.com/abstract=4025932> (visited on 03/15/2022).
- Reyné, Bastien et alii (Mar. 2022). “Non-Markovian modelling highlights the importance of age structure on Covid-19 epidemiological dynamics”. en. In: *Mathematical Modelling of Natural Phenomena*. Publisher: EDP Sciences. ISSN: 0973-5348, 1760-6101. DOI: [10.1051/mmnp/2022008](https://doi.org/10.1051/mmnp/2022008). URL: <https://www.mmnp-journal.org/articles/mmnp/abs/forth/mmnp220048/mmnp220048.html> (visited on 03/15/2022).
- Salje, Henrik et alii (July 2020). “Estimating the burden of SARS-CoV-2 in France”. In: *Science* 369.6500. Publisher: American Association for the Advancement of Science, pages 208–211. DOI: [10.1126/science.abc3517](https://doi.org/10.1126/science.abc3517). URL: <https://www.science.org/doi/10.1126/science.abc3517> (visited on 09/25/2021).
- UKHSA (2022). “COVID-19 vaccine surveillance report - week 16”. en. In: *Report*, page 22. URL: <https://www.gov.uk/government/publications/covid-19-vaccine-weekly-surveillance-reports>.
- UKSHA (2022). “SARS-CoV-2 variants of concern and variants under investigation”. en. In: page 33. URL: <https://www.gov.uk/government/publications/investigation-of-sars-cov-2-variants-technical-briefings>.
- Verity, Robert et alii (June 2020). “Estimates of the severity of coronavirus disease 2019: a model-based analysis”. English. In: *The Lancet Infectious Diseases* 20.6. Publisher: Elsevier, pages 669–677. ISSN: 1473-3099, 1474-4457. DOI: [10.1016/S1473-3099\(20\)30243-7](https://doi.org/10.1016/S1473-3099(20)30243-7). URL: [https://www.thelancet.com/journals/laninf/article/PIIS1473-3099\(20\)30243-7/abstract](https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30243-7/abstract) (visited on 06/02/2021).